Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension
Kids MoD PAH
What is the goal of the study?
In this study, we will compare the safety and efficacy of two treatment strategies in pediatric subjects with a new diagnosis of Pulmonary Arterial Hypertension: 1) first-line combination therapy (sildenafil and bosentan); versus 2) first-line monotherapy (sildenafil alone). Efficacy will be assessed by WHO functional class (FC) at twelve months after initiation of study drug therapy.
Who can participate in the study?
Please contact the study team listed below to learn more.